Key result
Random forest machine learning identifies cardiac amyloidosis with an AUROC of ~0.97.
Why the study?
Cardiac amyloidosis is frequently underdiagnosed due to heterogeneous presentation and complex diagnostic algorithms, while existing machine learning screening models often function as black boxes or require resource-intensive inputs that limit clinical adoption.
Does a threshold-optimised random forest pipeline using 15 routine non-invasive parameters accurately identify cardiac amyloidosis in adult patients with unexplained heart failure referred for myocardial biopsy?
Observational (n=952)
No
Does a threshold-optimised random forest pipeline using 15 routine non-invasive parameters accurately identify cardiac amyloidosis in adult patients with unexplained heart failure referred for myocardial biopsy?
Answers are grounded in this paper and cite their sources.
An explainable random forest model using 15 routine non-invasive parameters can accurately screen for and safely rule out cardiac amyloidosis (NPV 98.8%) in patients with unexplained heart failure, potentially reducing unnecessary invasive biopsies.
Background Cardiac amyloidosis (CA) is an increasingly recognised but frequently underdiagnosed cause of heart failure, largely due to its heterogeneous clinical presentation and the complexity of current multimodal diagnostic algorithms. Because delayed recognition is associated with rapid disease progression and poor prognosis, early and accessible screening is vital. While machine learning (ML) offers a potential solution for early diagnostics, existing models often function as "black boxes" or rely on resource-intensive inputs, limiting real-world clinical adoption. This study aimed to develop and internally validate a transparent, high-sensitivity ML pipeline to identify patients at risk of CA using only routinely available, non-invasive clinical parameters. Methods We conducted a retrospective derivation and validation study using electronic health records from 952 adult patients with unexplained heart failure who were referred for myocardial biopsy at a tertiary centre (100 positive CA cases). A random forest pipeline was developed using 15 strictly selected features encompassing demographics, standard biomarkers, routine laboratory panels, and basic echocardiographic parameters. Class imbalance was addressed using an optimised algorithmic class weighting strategy, which proved superior to synthetic oversampling in a 10-fold cross-validated ablation study. Model explainability was audited using Shapley Additive exPlanations (SHAP). Results In the final held-out test evaluation, the optimised pipeline achieved a robust area under the receiver operating characteristic curve (AUROC) of 0.967 and an area under the precision-recall curve (AUPRC) of 0.767. To prioritise clinical safety and minimise missed diagnoses, an optimised decision threshold (0.34) was applied (Figure A), yielding a sensitivity of 90.0%, specificity of 94.1%, and a negative predictive value (NPV) of 98.8% (Figure B). Global SHAP analysis confirmed the model’s clinical validity (Figure C); predictions were driven by established pathophysiological hallmarks, including advanced age, structural pseudohypertrophy (interventricular septal thickness (IVSd) and left ventricular posterior wall thickness (LVPWd)), a proxy for wall stress (BNP), and relative preservation of left ventricular ejection fraction (LVEF). Furthermore, patient-level risk audits successfully decomposed these clinical features to explain individual predictions (Figure D). Conclusion Our threshold-optimised machine-learning approach provides a highly accurate, interpretable screening tool for cardiac amyloidosis. By relying exclusively on 15 routine, non-invasive parameters and achieving an NPV of 98.8%, this explainable AI tool allows clinicians to safely rule out CA, reducing the need for unnecessary invasive workups and accelerating the time-to-diagnosis for true positive cases.1. Threshold optimization and performance2. SHAP model explainability
No takes yet. Share an insight, caveat, or question.
Tuennermann et al. (2026) conducted an observational in Cardiac amyloidosis in unexplained heart failure (n=952). Threshold-optimised random forest machine learning pipeline using 15 routine non-invasive parameters vs. Myocardial biopsy diagnosis was evaluated on Diagnostic performance for identifying cardiac amyloidosis (AUROC 0.967). A threshold-optimised random forest pipeline identified cardiac amyloidosis with an AUROC of 0.967, sensitivity of 90.0%, specificity of 94.1%, and NPV of 98.8%.
Synapse has enriched 10 related papers. Consider them for comparative context: